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Key questions
What is already known about this subject?
 ► Biosimilars may potentially reduce care costs and 
improve patient access.
 ► However, uptake of biosimilars in oncology has been 
limited by safety concerns.
 ► In particular, surrounding switching from a biosim-
ilar to its reference medicine or vice versa, and a 
lack of understanding around the requirements for 
development, including extrapolation of indications.
What does this study add?
 ► This European Society for Medical Oncology survey 
found encouraging levels of prescriber use and gen-
eral knowledge of biosimilars; however, a substan-
tial need for further education remains, especially 
for improving prescriber understanding of extrapo-
lation of indications.
 ► Discrepancies in responses were found among Asia-
Pacific and European prescribers.
 ► Asia-Pacific prescribers appear more confident in 
their understanding of the biosimilar development 
process, the concept of extrapolation of indica-
tions and switching, but less confident on European 
Medicines Agency definitions.
 ► A worldwide effort should be undertaken to align 
definitions and regulatory standards.
How might this impact on clinical practice?
 ► Educational initiatives focused on the knowledge 
gaps identified in this survey are essential for suc-
cessful integration and uptake of biosimilars in 
oncology, which can potentially improve the sustain-
ability of cancer care by increasing the accessibility 
of therapeutic and supportive care and providing 
lower-cost alternatives to their reference medicines.
AbstrAct
Background Biosimilars can potentially improve 
the sustainability of cancer care; however, uptake is 
sometimes limited by safety concerns and a lack of 
understanding of the concept of extrapolation. The 
European Society for Medical Oncology (ESMO) conducted 
a survey to assess the current level of knowledge, 
understanding and comfort of use of biosimilars among 
prescribers specialised in oncology.
Methods A 19-question survey was developed using 
the SurveyMonkey online platform (https://www. 
surveymonkey. com/). Data collection occurred between 
September and October 2017 and included paper and 
online responses.
Results Overall, 393 responses were received from 
prescribers. Overall, 49.0% of prescribers use biosimilars 
in clinical practice and most (79.2%) rate their general 
knowledge of biosimilars as average to very high. Potential 
increased risk of immunogenicity remains a significant 
concern of switching. Gaps in knowledge identified by the 
survey include biosimilar development, clinical trial design 
and endpoint selection, and requirements for extrapolation, 
which should form the focus of future educational 
initiatives. A substantial demand remains for further 
educational activities with equal preference for online and 
face-to-face initiatives. A higher rate of biosimilar use 
(56.3% vs 46.5%), knowledge of biosimilar development 
and trial design, and comfort with extrapolation, but 
a lower knowledge of European Medicines Agency 
definitions, was found among prescribers from Asia-Pacific 
versus those from Europe.
Conclusion Encouraging levels of prescriber use and 
general knowledge of biosimilars were found, but a 
substantial need for further education remains. Efforts 
should be made worldwide to align terms, definitions and 
guidelines for the development and approval of biosimilars.
IntRoduCtIon
Cancer treatment has been advanced by, but 
become reliant on, biologics.1 2 Biologics are 
typically large proteins such as monoclonal 
antibodies, interferons and recombinant 
hormones.3 Processes for biologic production 
involve living systems and complex proce-
dures requiring the utmost precision to guar-
antee final product consistency and quality.3 4 
These complex manufacturing processes, as 
well as their long development times, result 
in biologics being expensive,2 5 adding to the 
already high costs of cancer treatment.
Cancer care cost is rapidly becoming a 
significant issue driven by rising cancer inci-
dence, ageing populations and the increasing 
price of treatments.5 Patent expiration has 
occurred or is approaching for many biologics 
used in oncology.6 It has been proposed that 
the sustainability of cancer care worldwide 
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can potentially be improved through the use of safe and 
effective biosimilars, which expand the treatment options 
available to clinicians and patients, increase accessibility 
of therapeutic and supportive care, and provide lower-
cost alternatives to their reference medicines.2 5 7 8
A biosimilar is a biologic that matches its reference 
medicine in terms of quality, activity, safety and effi-
cacy.9–11 In 2006, a recombinant human growth hormone 
(Omnitrope) was the first biosimilar to receive Euro-
pean Medicines Agency (EMA) approval,12 followed by 
EMA approval of biosimilars for epoetin alfa in 2007 
and recombinant human granulocyte colony-stimulating 
factor (rhG-CSF) in 2009.13 14 The biosimilar rhG-CSF 
(Zarxio) was the first biosimilar to receive approval from 
the US Food and Drug Administration (FDA).15
Regulatory requirements for biosimilars are evolving 
and becoming more familiar among healthcare profes-
sionals (HCPs). The EMA, FDA and WHO require 
substantial evidence demonstrating that a biosimilar 
matches its reference medicine.9–11 The objective of a 
biosimilar development programme is to demonstrate no 
clinically meaningful differences based on the ‘totality of 
evidence’ approach, that is, a comprehensive comparison 
of the proposed biosimilar and the reference medicine 
with respect to structure, function, pharmacokinetics, 
pharmacodynamics, clinical immunogenicity, safety 
and efficacy.9–11 Unlike the standard requirements for 
drug approval, the development process for biosimilars 
demands a relatively larger amount of preclinical than 
clinical data.
Despite the potential for reducing care costs and 
improving patient access, uptake of biosimilars in oncology 
has been limited potentially by a lack of understanding 
of their development and of the regulatory assessment, 
including requirements for extrapolation of indications.7 
Extrapolation is the approval, by a regulatory agency, of 
a biosimilar in one or more indications of the reference 
biologic without the requirement to carry out clinical 
trials of the biosimilar in all those indications.16 17 If simi-
larity between the biosimilar and its reference biologic is 
credibly shown through ‘totality of evidence’ in one indi-
cation, extrapolation permits approval of the biosimilar 
in all other indications held by the reference biologic.18 
Extrapolation has the potential to reduce the costs asso-
ciated with biosimilar development, increasing access to 
biologic therapies and reducing cancer care costs.7
Uncertainties exist among HCPs regarding switching, 
the decision to administer a biosimilar in a patient previ-
ously treated with the reference biologic or vice versa, 
and the potential for reduced efficacy or increased 
immunogenicity in both the oncology and non-oncology 
settings.3 19–22
In order to assess the current knowledge, under-
standing and comfort of use of biosimilars in oncology, 
with a particular focus on extrapolation and switching, 
the European Society for Medical Oncology (ESMO) 
conducted a survey among its members and attendees at 
the 2017 ESMO Congress in Madrid, Spain.
MetHods
ESMO developed a 19-question survey using the Survey-
Monkey online platform (https://www. surveymonkey. 
com/), which sought information regarding responders’ 
use and basic knowledge of biosimilars, understanding of 
biosimilar development and level of comfort with extrap-
olation, interchangeability and switching (see online 
supplementary appendix).
Data collection occurred between September and 
October 2017 and included both paper and online 
responses. During the ESMO 2017 Congress, attendees 
completed paper copies of the survey; results were then 
inputted into the SurveyMonkey platform. Additionally, 
a link to the online survey was sent in an email to ESMO 
members and their wider professional network. Results 
were summarised using descriptive statistics.
The survey contained a mixture of checkbox answers 
and questions asking responders to rank their level of 
agreement, knowledge, comfort or importance of each 
statement from 1 to 5 or 10. For these questions, results 
were pooled and a weighted average (WA) score out of 
5 or 10 was assigned. An open comments box at the end 
of the survey asked responders to provide suggestions for 
future educational initiatives.
Results
demographics, basic knowledge and use
Overall, 495 responses were collected. Of the 480 
responders who mentioned their country, most were 
from Europe (n=321), then Asia (n=84), America (n=55), 
Africa (n=13) and Australia (n=7).
These analyses include responses from prescribing physi-
cians only and evaluate responses from all prescribers, 
European and Asia-Pacific prescribers. Overall, 80.0% 
(393/491, 4 skipped) of responders were prescribing 
physicians (Europe: 79.7%, n=255; Asia-Pacific: 87.9%, 
n=80), with most being ESMO members (92.0%, n=357) 
and specialised in oncology (94.3%, n=367).
When asked to rate their overall knowledge of biosim-
ilars, the most commonly selected option on a scale of 1 
(very low) to 5 (very high) was option 3 (45.5%, 177/389, 
4 skipped; figure 1A). Options 3, 4 and 5 were selected 
by 79.2% (n=308; sum of responses) of prescribers indi-
cating that most consider themselves to have an average 
to very high level of knowledge of biosimilars. In total, 
74.6% (291/390, 3 skipped) of prescribers were able to 
identify the most appropriate definition of ‘biosimilar’ 
(‘highly similar to an approved biological medicine, with 
no clinically meaningful differences in safety and efficacy 
profile’). This definition was selected by 77.9% (197/253, 
2 skipped) of European and 64.6% (51/79, 1 skipped) of 
Asia-Pacific prescribers.
Overall, 49.0% (191/390, 3 skipped) of prescribers use 
biosimilars in routine clinical practice (excluding clinical 
trials; figure 2). A higher proportion of prescribers from 
Asia-Pacific (56.3%, 45/80) use biosimilars versus those 
from Europe (46.5%, 118/254, 1 skipped; figure 2). 
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Figure 1 Prescribers’ responses rating their level of knowledge/understanding on a scale of 1–5. Prescribers’ responses, by 
region, when asked to rate their knowledge/understanding of (A) biosimilars overall; (B) the biosimilar development process 
and threshold of clinical evidence required for approval; (C) clinical trial design and endpoint selection for biosimilar studies; 
(D) requirements needed to be met for extrapolation of indications to be granted for a biosimilar.
Compared with the entire European group, rate of use was 
lower among prescribers from the UK (31.3%, 10/32). 
Biosimilars are not used by 24.1% (94/390, 3 skipped) of 
prescribers due to lack of approval or reimbursement in 
their country (figure 2).
On a scale of 1 (not at all) to 5 (very), prescribers were 
asked to rate their comfort with the concept of using an 
EMA-approved biosimilar to treat a patient suitable for 
the reference biologic. Options 4 and 5 were chosen 
by 57.4% (217/378, 15 skipped, sum of responses) of 
prescribers (figure 3A).
Biosimilar development
Most prescribers feel they have an average to moderate 
level of knowledge of the biosimilar development 
process and the threshold of clinical evidence required 
for approval of a biosimilar, with 61.1% (204/334, 59 
skipped, sum of responses) selecting options 3 and 4 on 
a scale of 1 (very low) to 5 (very high; figure 1B). Option 
3 was the most frequent choice by Asia-Pacific and Euro-
pean prescribers (43.9% vs 37.0%; figure 1B) with the 
second most commonly selected choices being option 4 
(24.2%) and option 2 (22.2%), respectively (figure 1B).
Clinical safety and efficacy data are the best under-
stood data types by all prescribers (WA [out of 5] 3.67), 
followed by immunogenicity data (WA 3.10). However, 
the two regions differed on the least understood type of 
data (Europe: physicochemical, WA 2.64; Asia-Pacific: 
in vitro, WA 2.36). In addition, clinical study safety (WA 
[out of 10] 8.80) and efficacy (WA 8.65; table 1) data are 
considered the most important among prescribers in 
determining the suitability of a biosimilar for use. The 
type of data considered least important is physicochem-
ical data demonstrating structural similarity (WA 7.23; 
table 1).
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Figure 2 Level of routine use of biosimilars by prescribers in clinical practice to treat patients.
Figure 3 Prescribers’ responses rating their level of comfort on a scale of 1–5. Prescribers’ responses, by region, when 
asked to rate their comfort with (A) the concept of using an EMA-approved biosimilar to treat a patient suitable for the 
reference biologic; (B) using an EMA-approved biosimilar in extrapolated indications that the reference biologic is approved 
for. EMA, European Medicines Agency.
From three options, 45.2% (146/323, 70 skipped) 
of prescribers were able to select the most appropriate 
definition of ‘sensitive indication’ in terms of biosimilar 
development (‘the population that is most representative 
of the patients to whom the biologic is most frequently 
prescribed’). This definition was selected by 42.1% 
(88/209, 46 skipped) of European and 60.0% (39/65, 15 
skipped) of Asia-Pacific prescribers. The second preferred 
definition (‘a population where product-related differ-
ences in clinical performance can be best detected’) was 
chosen by 31.3% (101/323, 70 skipped) of all prescribers 
(Europe: 33.5%, 70/209, 46 skipped; Asia-Pacific: 26.2%, 
17/65, 15 skipped).
On a scale of 1 (very low) to 5 (very high), responses 
suggest that most prescribers feel they have an average 
to moderate level of knowledge regarding clinical trial 
design and endpoint selection for biosimilar studies, with 
59.8% (195/326, 16 skipped, sum of responses) selecting 
options 3 and 4 (figure 1C). Nearly half of the prescribers 
(49.7%, 161/324, 69 skipped) chose ‘the endpoint consid-
ered most sensitive for detecting differences between the 
biosimilar and reference biologic, and least influenced by 
patient or disease-related factors’ as the most appropriate 
for studies comparing the clinical efficacy of a biosimilar 
with its reference medicine.
Moreover, 33.4% (108/323, 70 skipped) of prescribers 
feel that the most appropriate indication for a study 
comparing the clinical efficacy and safety of a biosimilar 
with a reference biologic is ‘the indication representing 
the most sensitive population for detecting any potential 
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Table 1 Prescribers’ responses rating the importance and sensitivity of different data types in determining the suitability of a 
biosimilar for use
Type of data (weighted average)
Importance Sensitivity
All Europe Asia-Pacific All Europe Asia-Pacific
Physicochemical data demonstrating 
structural similarity
7.23 7.05 7.30 7.24 7.07 7.56
In vitro and in vivo data demonstrating 
similarity in biological activity
7.76 7.74 7.66 7.58 7.46 7.82
PK and PD data demonstrating 
similarity
7.94 7.85 8.10 7.83 7.75 8.10
Clinical study data demonstrating 
similar efficacy
8.65 8.56 8.72 8.61 8.57 8.75
Clinical study data demonstrating 
similar safety
8.80 8.78 8.83 8.75 8.72 8.79
Clinical study data demonstrating 
similar immunogenicity
8.24 8.24 8.10 8.30 8.23 8.41
Clinical study data demonstrating 
the ability to switch from reference 
to biosimilar and vice versa without 
impairing safety or efficacy
8.07 8.02 8.27 8.11 8.02 8.36
Weighted average of prescribers’ responses, by region, on a scale of 1 (not important/sensitive) to 10 (very important/sensitive).
PD, pharmacodynamic; PK, pharmacokinetic.
difference between the products’. The next most frequent 
response, selected by 27.9% (90/323, 70 skipped), was 
‘comparative efficacy and safety should be studied in 
every indication of the reference biologic’, suggesting 
that there is a lack of understanding surrounding the 
concept of extrapolation of indications.
extrapolation of indications
Most prescribers (61.7%, 192/311, 82 skipped) were able 
to identify the most appropriate definition of ‘extrap-
olation of indications’ (‘authorisation of a biosimilar 
in indications of the reference biologic in the absence 
of specific clinical trial/data for the biosimilar in those 
indications’). Fewer Asia-Pacific prescribers selected this 
definition versus European prescribers (53.2% vs 65.4%), 
although it was the preferred option in both groups.
Despite the high proportion of prescribers being able to 
define ‘extrapolation of indications’, most consider their 
understanding of extrapolation to be below average, with 
62.3% (190/305, 88 skipped, sum of responses) selecting 
options 2 and 3 on a scale of 1 (very low) to 5 (very high; 
figure 1D).
Overall, responses indicate that prescribers feel 
comfortable using a biosimilar in an extrapolated indi-
cation. On a scale of 1 (not at all) to 5 (very), options 
3, 4 and 5 were chosen by 76.7% (237/309, 84 skipped, 
sum of responses) of prescribers (figure 3B). These three 
options were chosen by 74.3% (150/202, 53 skipped, 
sum of responses) of European and 82.8% (53/64, 16 
skipped, sum of responses) of Asia-Pacific prescribers 
(figure 3B), indicating that Asia-Pacific prescribers may 
feel more comfortable with the concept of extrapolation 
than those from Europe.
Interchangeability and switching
Respondents were presented with correct EMA defini-
tions of interchangeability and switching, and an incor-
rect definition of substitution. Only 36.3% (110/303, 90 
skipped) of prescribers were able to identify the incor-
rect definition and the other two correct definitions were 
also widely chosen (interchangeability: 29.7%, 90/303, 90 
skipped; switching: 34.0%, 103/303, 90 skipped). Similar 
proportions of European (36.0%, 71/197, 58 skipped) 
and Asia-Pacific (35.5%, 22/62, 18 skipped) prescribers 
were able to successfully identify the incorrect definition 
of substitution. However, the same proportion of Asia-Pa-
cific prescribers (35.5%, 22/62, 18 skipped) believed the 
definition of switching was incorrect.
Regarding switching a patient from a biosimilar to 
a reference biologic or vice versa, the statement most 
agreed with by prescribers was “I do not anticipate that 
switching will have a significant effect on the treatment 
benefit the patient receives from the product” (WA 
[out of 5] 3.50). This statement was the most commonly 
chosen option by both European (WA 3.47) and Asia-Pa-
cific prescribers (WA 3.55). However, among prescribers 
from Asia-Pacific, there was a similar level of agreement 
(WA 3.54) with the statement “I do not anticipate that 
switching will lead to emergence of additional adverse 
events”.
Among all prescribers, equal levels of concern were 
expressed for the potential for adverse events (AEs) 
and increased risk of immune reactions when switching 
(WA 3.35; table 2). European prescribers were mainly 
concerned with the potential increased risk of immune 
reactions (WA 3.39) whereas Asia-Pacific prescribers 
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Table 2 Prescribers’ responses rating their concern 
of potential consequences when switching a patient’s 




(weighted average) All Europe Asia-Pacific
Potential loss of 
clinical efficacy
3.29 3.23 3.30
Potential for adverse 
events
3.35 3.32 3.35
Potential for increased 
risk of immune 
reactions
3.35 3.39 3.17
Weighted average of prescribers’ responses, by region, on a scale 
of 1 (not at all) to 5 (very).
Table 2 Prescribers’ responses rating their concern 
of potential consequences when switching a patient’s 




(weighted average) All Europe Asia-Pacific
Potential loss of 
clinical efficacy
3.29 3.23 3.30
Potential for adverse 
events
3.35 3.32 3.35
Potential for increased 
risk of immune 
reactions
3.35 3.39 3.17
Weighted average of prescribers’ responses, by region, on a scale 
of 1 (not at all) to 5 (very).
were primarily concerned with potential AEs (WA 3.35; 
table 2), despite a high level of agreement with not antici-
pating additional AEs on a switch in the previous question.
Further education
Overall, 86.7% (195/225, 168 skipped) of prescribers 
would like ESMO to provide more educational activities 
concerning biosimilars; a much higher proportion of 
Asia-Pacific prescribers expressed this (97.9%, 47/48, 32 
skipped) versus European prescribers (82.9%, 121/146, 
109 skipped).
Prescribers suggested numerous topics for future 
educational activities, including clinical trial design and 
endpoints, bioequivalence criteria and studies, approval 
procedures, principles of pricing and reimbursement, 
and treatment outcome comparisons between biosimilars 
and their reference medicines. Communication chan-
nels suggested included online educational activities and 
materials (courses, quizzes, articles, guideline handbooks 
and updates on key developments; n=56) and face-to-face 
educational activities (congress sessions, preceptorships, 
workshops and seminars; n=51). European prescribers 
communicated a higher interest in receiving training on 
the efficacy and safety of biosimilars while Asia-Pacific 
prescribers were more interested in training tailored for 
developing countries.
dIsCussIon
This ESMO survey shows that nearly half of prescribers 
(49.0%) use biosimilars in their clinical oncology prac-
tice; lack of approval and reimbursement is a barrier to 
use. Responses suggest that most prescribers (79.2%) feel 
they have an average to very high level of general biosim-
ilar knowledge, with nearly three quarters (74.6%) able 
to identify the most appropriate definition of ‘biosimilar’. 
Overall, 57.4% of prescribers feel comfortable using an 
EMA-approved biosimilar.
Most prescribers feel they only have an average to 
moderate level of knowledge about biosimilar devel-
opment, the level of clinical evidence required for a 
biosimilar approval, clinical trial design and selection of 
endpoints; these therefore present as topics for future 
educational activities. Indeed, less than half (45.2%) of 
prescribers were able to identify the most appropriate 
definition of ‘sensitive indication’. Uncertainties were 
also demonstrated in differentiating ‘interchangeability’, 
‘substitution’ and ‘switching’. Despite nearly two-thirds of 
prescribers being able to identify the most appropriate 
definition of ‘extrapolation of indications’, most rated 
their understanding of the requirements for extrapo-
lation of indications as below average. However, most 
prescribers feel comfortable using a biosimilar in an 
extrapolated indication. Therefore, it seems that many 
prescribers trust and accept the scientific principle of 
extrapolation though may not fully understand it.
The main concerns oncology prescribers have with 
switching are the potential for AEs and increased risk 
of immune reactions. Currently, the majority of data 
available on switching are from real-world and clinical 
studies in immune-mediated inflammatory diseases, such 
as rheumatoid arthritis, inflammatory bowel disease and 
psoriasis, which have found no clinically meaningful 
effects when switching between a biosimilar and its refer-
ence biologic.23–42 Presently, there is one published study 
on switching in oncology, which reported no meaningful 
differences in efficacy, safety or immunogenicity when 
switching biosimilar rhG-CSF with its reference biologic 
to prevent severe neutropenia in patients with breast 
cancer undergoing myelosuppressive chemotherapy.43 A 
recent systematic literature review of 90 switching studies, 
treating 14 disease indications and enrolling over 14 000 
patients and healthy volunteers, concluded that there is 
little risk of increased immunogenicity or treatment-re-
lated AEs, or reduction in efficacy, when switching 
between reference medicines and biosimilars.21 An 
increase in the confidence of switching biosimilar medi-
cines with their reference biologics among the oncology 
community, like in other disease areas, may occur after 
increased availability of results from further real-world 
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data and world-evidence studies that will ultimately help 
to guide clinical decision-making.
Regarding knowledge, use and comfort with biosimi-
lars, some differences in responses were found between 
European and Asia-Pacific prescribers. First, a higher rate 
of biosimilar use in routine clinical practice was found 
among Asia-Pacific (56.3%) versus European prescribers 
(46.46%). This may be a result of numerous regulatory 
bodies in Asia heavily investing in accelerated development 
of biosimilars.44 Furthermore, a lower rate of biosimilar 
use was found among prescribers from the UK (31.3%) 
compared with the whole group of European prescribers. 
Responses also suggest that Asia-Pacific prescribers may 
be more confident in their understanding of biosimilar 
development than European prescribers.
However, in most questions concerning EMA defi-
nitions, a lower proportion of Asia-Pacific prescribers 
answered correctly versus European prescribers. The 
only instance where this was not the case was the defi-
nition of ‘sensitive indication’, correctly answered by 
60.0% of Asia-Pacific and 42.1% of European prescribers, 
indicating that Asia-Pacific prescribers may have a better 
understanding of the clinical evidence required for a 
biosimilar to gain approval and clinical trial design. Lastly, 
responses suggest that prescribers from Asia-Pacific are 
more comfortable with the concept of extrapolation than 
those from Europe.
These differences in responses, particularly regarding 
EMA definitions, may be a result of differing guidelines 
available on biosimilars in each region. Europe follows 
standardised regulations outlined by the EMA for biosim-
ilar approval whereas the regulations in Asia-Pacific coun-
tries differ greatly in the data types required.44 Since 
2008, guidance ensuring the quality, safety and efficacy 
of biosimilar medicines has been available in the Asia-Pa-
cific region.45 EMA guidance was followed initially in 
many countries in the Asia-Pacific region prior to them 
implementing their own individual guidelines.45 Coun-
tries including South Korea, Japan and Malaysia estab-
lished their own guidance by taking elements from EMA 
and WHO guidelines.45–48 In August 2016, India updated 
its initial guidance originally published in 2012 to ensure 
a clearer and more thorough regulatory pathway, and to 
make parallel with other guidelines available around the 
world.49
Currently, the requirements outlined by regulatory 
authorities in different regions regarding biosimilar 
approval vary.9 47 A worldwide effort should be under-
taken to align definitions and standards for the develop-
ment and approval of biosimilars. This could potentially 
reduce confusion surrounding scientific terms and 
concepts, lead to better understanding of the biosimilar 
development process and ultimately increase accessibility 
and affordability of cancer care.8
Differences in responses were also noted between 
prescribers specialised in oncology and haematology. 
Of the 393 prescribers who responded, 22 (5.6%) were 
specialised in haematology. Overall, knowledge of 
biosimilar development and trial design, as well as under-
standing and comfort of extrapolation of indications, 
were similar between prescribers specialised in oncology 
and haematology. However, a higher proportion of 
haematology versus oncology prescribers feel they have 
a high to very high level of comfort using an EMA-ap-
proved biosimilar (72.8% vs 57.4%) and use biosimilars 
in routine practice (63.6% vs 49.0%).
Overall, the level of prescriber knowledge on biosimi-
lars ascertained by this survey is encouraging. However, 
a substantial need for continued education emerged 
as well. Future efforts should focus in particular on 
improving prescriber understanding of extrapolation of 
indications as well as physicochemical data, which was 
found to be the least understood data type in determining 
the suitability of a biosimilar for use when in fact it is 
considered by regulatory authorities as the most determi-
nant data type required. This survey found a substantial 
demand among prescribers for educational activities and 
materials regarding biosimilars, especially in Asia-Pacific. 
Responses suggest that preference is fairly even between 
online (56 responses) and face-to-face (51 responses) 
educational activities. The low response to this question 
is potentially due to its open comment box design which 
is more demanding for respondents and, being the final 
question, it is feasible that responders ran out of time. 
Prescribers from the two different regions had differing 
preferences for topics that future training initiatives 
should focus on. European prescribers displayed a high 
interest in receiving training on the efficacy and safety 
of biosimilars, while many from Asia-Pacific conveyed an 
interest for more training adapted for developing coun-
tries. ESMO is undertaking a range of educational initia-
tives including two previous sessions during the ESMO 
2017 meeting in Madrid and ESMO Asia 2017, and 
another two Colloquia during the 2018 annual meeting 
in Munich, Germany, and ESMO Asia 2018, to improve 
the understanding of biosimilars within the community. 
ESMO is also working on developing patient materials to 
help their understanding of biosimilars.
Limitations of the survey include the fact that no 
hypothesis was tested and the questionnaire was purely 
developed to document the current level of biosim-
ilar knowledge, use and comfort; not all replies were 
complete, so data could not be analysed in its entirety; and 
responses were limited to ESMO members, their wider 
network and participants at the ESMO 2017 Congress, so 
may not accurately represent all prescribers worldwide.
ConClusIon
In conclusion, this survey conducted by ESMO found an 
encouraging level of prescriber use and general knowl-
edge of biosimilars in oncology; however, need for further 
education remains. Future educational initiatives should 
focus on improving prescriber understanding of extrapo-
lation of indications as well as physicochemical data.
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Lastly, some differences in responses between Euro-
pean and Asia-Pacific prescribers may be attributed to 
differences in guidance available in the two regions. 
Efforts should be made worldwide to align definitions and 
regulatory standards for the development and approval 
of biosimilars. Continued education will lead to more 
informed discussion and decision-making regarding 
biosimilars, which will help their successful integration 
and uptake in oncology.8
Correction notice This article has been corrected since it first published online. 
The open access licence type has been amended.
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